natural pharmaceuticals derived From Cannabis and other medicinal plants

Filed Clinical Trial Application for Topical Product for the Treatment of Chemotherapy-Induced Neuropathic Pain

Sponsored
Tetra Bio-Pharma Inc. Profile

Tbp_large

Pharmaceutical Division – PhytoPain Pharma

  • Developing and commercialization of botanical based pharmaceuticals
  • Engaged in the development of medication to alleviate symptoms related to: Pain, Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases

Recent Highlights

  • Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
  • For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001
  • Acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • Pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

PRODUCT PIPELINE

Insomnia Management For Patients With Chronic Pain

  • Licensed a hypnotic drug from Mondias Naturals Inc
  • Management of Insomnia in patients with chronic pain
  • Currently in late stage Phase III clinical testing

PhytoPain To Produce A Combination Product

  • Proprietary combination expected to reach Phase I clinical testing in 2017
  • Will be ready for market in 2017 due to combination with Mondias Naturals product

Pain Management - Inhalation Cannabis Drug Product

  • A prescription drug for management of uncontrolled pain in cancer patients
  • Health Canada will provide guidance during Phase I clinical trial
  • Commencing December 2016. Anticipating 3-5 year product development

A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.

OPERATIONS OVERVIEW - MMPR

MMPR Division - Collaboration Agreement

  • National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University.
  • MP will establish a first research collaboration with McGill University and plans to invest in this program both financially and with in-kind contributions to pursue its research and development objectives and become a world leader in the development and commercialization of Cannabis-based products
  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller

Last changed at 11-Nov-2016 12:05PM by AGORACOM